Catalyze and BioHealth Innovation have entered an agreement to actively bridge the Life Sciences communities in the US and the EU. This transatlantic partnership will increase opportunities for translating biohealth discoveries to market through grant writing services, expanded technology commercialization and international soft-landing support. The two parties have a wide range of resources and knowledge which combined will better aid in delivering high-impact, customer-specific solutions.<\/p>\n\n\n\n
BioHealth Innovation, based in Maryland, USA, is renowned for its efforts to source and evaluate market-relevant biohealth intellectual properties, connecting the IP with non-dilutive and early stage funding sources, and assisting businesses with marketing, funding applications and other resources for business growth. Richard Bendis, Founder, President and CEO of BioHealth Innovation: \u201cWe are excited to augment our resources for early stage companies with those of the Catalyze team.\u201d<\/p>\n\n\n\n
Catalyze Founder and Director Theodoor Rutgers: \u201cThis new partnership with BioHealth Innovations creates added value on a global scale. We are happy to be expanding in the US, bridging R&D innovations across the Atlantic.\u201d Catalyze is a market leader in obtaining non-dilutive funding for biomedical and healthcare innovations. The Amsterdam-based company has built a network of more than 2,000 partners around the world, raising over half a billion Euro in funding for clients. According to Catalyze Commercial Director Quirein te Roller: \u201cThis is a unique opportunity for us to leverage the strengths of both parties, enabling more innovations and better innovations, to make it to market faster, effectively changing the lives of millions around the world.\u201d<\/p>\n\n\n\n